Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Proxy Solicitation & Information Statement 2021

Apr 13, 2021

30583_rns_2021-04-13_83ef20ee-6e31-4941-82b8-a9973e732aff.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

DEFA14A 1 bmrn3796953-defa14a.htm DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant

CHECK THE APPROPRIATE BOX:
Preliminary Proxy Statement
Confidential, For Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Under Rule
14a-12

BioMarin Pharmaceutical Inc.

(Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

| PAYMENT OF FILING FEE (CHECK THE APPROPRIATE

BOX):
No fee
required.
Fee computed on table below per Exchange Act Rules
14a-6(i)(1) and 0-11.
1)
Title of each class of securities to which transaction
applies:
2)
Aggregate number of securities to which transaction applies:
3)
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
4)
Proposed maximum aggregate value of transaction:
5) Total fee paid:
Fee paid previously with
preliminary materials:
Check box if any part of the fee is
offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing
for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the form or schedule and the
date of its filing.
1)
Amount previously paid:
2)
Form, Schedule or Registration Statement No.:
3)
Filing Party:
4) Date
Filed:
BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949 ATTN: G. ERIC DAVIS, EVP & GENERAL COUNSEL
FLASHID-JOB#

You invested in BIOMARIN PHARMACEUTICAL INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 25, 2021.

Get informed before you vote View the Notice & Proxy Statement, Form 10-K, and CEO Stockholder Letter online OR you can receive a free paper or email copy of material(s) by requesting prior to May 11, 2021. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

For complete information and to vote, visit www.ProxyVote.com Control #

Meeting live via the Internet - please visit www.virtualshareholdermeeting.com/BMRN2021
  • Please check the meeting materials for any special requirements for meeting attendance.

Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items Board Recommends
1. Election of Directors
Nominees:
01 Jean-Jacques Bienaimé 05 Elaine J. Heron 09 Richard A. Meier For
02 Elizabeth M. Anderson 06 Maykin Ho 10 David E.I. Pyott
03 Willard Dere 07 Robert J. Hombach 11 Dennis J. Slamon
04 Michael Grey 08 V. Bryan Lawlis
2 To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2021. For
3 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. For
4 To approve an amendment to the 2017 Equity Incentive Plan, as amended. For
NOTE: Your proxy holder will also vote on any other business as may properly come before the meeting or any adjournment thereof.

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”.

FLASHID-JOB#